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Inflammation is a protective mechanism in response to injury and infection, which works to isolate and eliminate foreign material from the body. However, when inflammation becomes uncontrolled and non-resolving, normal tissue can be damaged either through the immune system attacking 'self' or as a result of chronic tissue injury. To limit pathogenesis and allow for repair processes, immunoregulatory mechanisms exist. One such example is the anti-inflammatory cytokine IL-10; a master regulator of immunity, that limits the production and release of pro-inflammatory cytokines and chemokines by macrophages, and the expression of antigen presenting molecules. 2 Dysregulation of IL-10 has been implicated with the development of many autoimmune disorders and is associated with increased immunopathology in response to infection. 3 Deficiency of IL-10 or its receptor leads to inflammation of the intestine in mice, 3 that is recapitulated in macrophage specific IL-10 -/-mouse lines. 4 Furthermore, genome-wide association studies (GWAS) have associated the IL-10 gene within the susceptibility locus for ulcerative colitis 5 and inflammatory bowel disease (IBD), but the mechanisms by which IL-10 mediates its effects are unknown. A recent study by Ip et al. 1 provide new evidence linking IL-10 in the control of macrophage function by its reprogramming of metabolic pathways to aid in the clearance of dysfunctional mitochondria, thereby inhibiting the pro-inflammatory response. The authors show that defective IL-10 signalling in macrophages in both mice and humans, results in IBD, through the accumulation of damaged mitochondria and dysregulated activation of the NLRP3 inflammasome. Several current studies have highlighted the crucial role of metabolic reprogramming in macrophage activation. This has been associated with mitochondrion reactive oxygen species (ROS) generation to promote a pro-inflammatory state 6 and Lipopolysaccharide (LPS)-induced glycolytic flux in controlling IL-10-induction via cell autonomous means to regulate macrophage nitric oxide (NO) production. 7 Additional studies have shown alterations in the regulatory relationship between mitochondria and the microbiome is found in Crohns disease. 8 The new findings by Ip et al., linking these processes together, highlight that IL-10 promotes the induction of mitophagy-the selective process of degradation of mitochondria by autophagy, suggesting that IL-10 plays a more direct role in maintaining mitochondrial integrity, which is important in preserving respiratory capacity. The inflammatory response can be influenced by metabolic reprogramming, that is initiated by activation of toll like receptors (TLR). In macrophages stimulated with LPS, a TLR4 ligand, aerobic glycolysis is activated, independent of mitochondrial oxidative phosphorylation. However, Ip and colleagues show IL-10 -/-macrophages have altered metabolic profiles after stimulation with LPS; increased glycolysis, and further reduced oxidative phosphorylation in comparison to control macrophages. This is combined with increased mitochondrial mass a result of the failure of mitophagy. As a product of oxidative phosphorylation, damaged mitochondria produce an increased level of ROS that causes cell damage. Glucose and lipid metabolism is controlled by crucial metabolic pathways such as the activation of mammalian target of rapamycin complex 1 (mTORC1) that regulates autophagy, a process important for removing damaged proteins and organelles. of exogenous IL-10. IL-10 inhibition of mTORC1 signalling was shown to occur via signal transducer and activator of transcription 3 (STAT3) suggesting the mechanisms of IL-10 regulation of mTORC1, occurred through transcription. Although IL-10 has been previously shown to engage in a metabolic regulatory loop to regulate M1 macrophage differentiation, 7 IL-10 has not previously been considered to mediate its effects by inhibiting mTORC1 activity in macrophages.
To translate these finding to disease, the authors isolated colonic lamina propria macrophages from IL-10 -/-mice with severe colitis and found these cells had increased mitochondrial ROS, accumulated damaged mitochondria and increased mTORC activation, similar to LPS treated IL-10 -/-macrophages. Further supported by studies in macrophages isolated from IBD patients with IL-10 receptor mutations, Ip et al. show these macrophages have sustained mTORC1 signalling and increased inflammatory cytokine IL-1b secretion. Collectively, these findings indicate that IL-10 rewires metabolism by decreasing LPS induced IL-1b expression by preventing ROS release from dysfunctional mitochondria and dampening inflammasome activation. These elegant studies by Ip et al., can assign mechanism and be corroborated to other inflammatory diseases ranging from rheumatoid arthritis, infectious diseases such as tuberculosis, and cardiovascular disease. Macrophages have a central role in cardiovascular disease states; from chronic inflammation such as atherosclerosis to acute inflammation in myocardial infarction and IL-10 has been shown to have multiple roles in both the vasculature and the heart. Most studies support the protective mechanism by IL-10; IL-10 -/-mice fed an atherogenic diet have increased lesions compared with wild-type mice. 10, 11 Macrophages in the atherosclerotic lesions are the main source of IL-10, where it plays a role in the modulation of the local inflammatory response for both macrophages and T cells, via mechanisms through inhibition of matrix metalloproteinases (MMPs) its anti-apoptotic properties and its modulation of lipid metabolism. Other roles for IL-10 in the vascular wall include acceleration of re-endothelialization and inhibition of post-injury intimal hyperplasia following carotid artery denudation, via differential regulation of endothelial and vascular smooth cell proliferation and function. 12 IL-10 also has protective roles in cardiac remodelling following cardiac injury. Following myocardial infarction (MI), exogenous IL-10 promotes post-MI repair by stimulating M2 macrophage polarization and increased fibroblast activation. By reducing inflammation in the heart post-MI, wound healing is facilitated. 13 Further studies of MI have indicated exogenous IL-10 suppresses infiltration of inflammatory cells and expression of pro-inflammatory cytokines in the injured myocardium. This contributes to improved left ventricular function and remodelling by inhibiting fibrosis via suppression of MMP-9 and increasing capillary density through activation of STAT3.
14 This new and emerging concept of linking IL-10 in macrophage metabolic reprogramming to mitophagy addressed in Ip et al., opens new perspectives in macrophage bioenergetics in cardiovascular inflammation, which is a relatively unexplored field to date. A better understanding would enable the identification of new therapeutic strategies aimed at targeting mitochondrial metabolism and the resolution of inflammation which will allow for modulation of the immune response in cardiovascular disease. In a study by Van den Bossche et al., 15 M1 macrophage activation reduced mitochondrial function, preventing the repolarization to an anti-inflammatory M2 phenotype. By inhibiting NO production, mitochondrial function is improved leading to metabolic reprogramming to M2 macrophages, which could be exploited therapeutically to reduce inflammation. Oxidative stress has long been recognized as a major player in the development of atherosclerosis and vascular disease states; however antioxidant interventions have failed to provide significant results in clinical studies. Alternatively, blockade of mitochondrial ROS production may serve as a therapy for inhibiting pro-inflammatory cytokine production. In light of these recent findings, IL-10 treatment and reprogramming of metabolism may have the potential to be a novel therapeutic agent against cardiovascular disease in the future.
